SLN360
Silence Therapeutics
[]
today at #aha22, our team is proud to announce a new analysis of our drug candidate to potentially treat high levels of lipoprotein(a) or #lpa, a key genetic risk factor for #heartdisease. see the analysis here: #silenceisgolden 
We are developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference. Nasdaq:SLN Guidelines: https://t.co/BplIZBk56w